We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

91 hedge funds and large institutions have $739M invested in BioCryst Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 24 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 24

33% more capital invested

Capital invested by funds: $555M → $739M (+$184M)

26% more call options, than puts

Call options by funds: $5.83M | Put options by funds: $4.63M

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

11% less funds holding

Funds holding: 102 → 91 (-11)

35% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 26

Holders
91
Holders Change
-11
Holders Change %
-10.78%
% of All Funds
2.43%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
17
Increased
32
Reduced
24
Closed
26
Calls
$5.83M
Puts
$4.63M
Net Calls
+$1.2M
Net Calls Change
+$789K

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$16.9M
2
QF
QVT Financial
New York
+$5.75M
3
State Street
State Street
Massachusetts
+$5.06M
4
Axa
Axa
France
+$3.6M
5
BFA
BlackRock Fund Advisors
California
+$2.83M

Top Sellers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.66M
2
CAM
Cormorant Asset Management
Massachusetts
-$3.31M
3
Jennison Associates
Jennison Associates
New York
-$3.14M
4
Morgan Stanley
Morgan Stanley
New York
-$2.51M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.45M
Name Holding Trade Value Shares
Change 		Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
26
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$2.59M +$483K +43,700 +26%
DCM
27
DAFNA Capital Management
California
$2.03M +$997K +90,256 +118%
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$1.77M +$177K +16,000 +11%
BG
29
BlackRock Group
United Kingdom
$1.74M +$21K +1,900 +1%
Macquarie Group
30
Macquarie Group
Australia
$1.73M +$482K +43,616 +44%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$1.58M +$6.11K +553 +0.4%
AllianceBernstein
32
AllianceBernstein
Tennessee
$1.31M – – –
USAA
33
United Services Automobile Association
Texas
$1.3M +$33.1K +3,000 +3%
SIA
34
Sit Investment Associates
Minnesota
$1.27M +$1.15M +104,525 New
FSA
35
Franklin Street Advisors
North Carolina
$1.2M +$66.3K +6,000 +6%
TA
36
Teachers Advisors
New York
$1.19M – – –
Millennium Management
37
Millennium Management
New York
$1.1M -$2.21M -199,846 -69%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$1.02M +$930K +84,226 New
IHM
39
Iguana Healthcare Management
New York
$912K +$828K +75,000 New
UBS Group
40
UBS Group
Switzerland
$858K +$780K +70,574 New
NPC
41
National Planning Corporation
California
$846K +$22.1K +2,000 +3%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$840K +$54.4K +4,929 +8%
CS
43
Credit Suisse
Switzerland
$819K -$9.05K -819 -1%
Swiss National Bank
44
Swiss National Bank
Switzerland
$806K +$26.5K +2,400 +4%
NFA
45
Nationwide Fund Advisors
Ohio
$799K +$131K +11,878 +22%
MSA
46
Mason Street Advisors
Wisconsin
$782K +$710K +64,300 New
BlackRock
47
BlackRock
New York
$774K – – –
ProShare Advisors
48
ProShare Advisors
Maryland
$761K -$23.9K -2,165 -3%
Morgan Stanley
49
Morgan Stanley
New York
$745K -$2.51M -227,022 -79%
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$665K – – –
1
2
3 4 5

BCRX Hedge Fund Activity: Q4 2014 in Review

91 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2014, worth a combined $739M — up 33% from $555M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of BCRX and 17 opened new positions — a net loss of 9 holders — while 24 trimmed existing stakes and 32 added.

The largest buyer was Wellington Management Group, adding an estimated $16.9M. The largest seller was D.E. Shaw & Co, cutting an estimated $4.66M.

  • 91 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2014, down from 102 in Q3 2014.
  • Funds reported $739M of BioCryst Pharmaceuticals stock for Q4 2014, up 33% quarter-over-quarter.
  • 17 funds opened new BioCryst Pharmaceuticals positions in Q4 2014 and 26 closed out, a net change of -9 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2014 was Wellington Management Group, an estimated $16.9M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2014 was D.E. Shaw & Co, an estimated $4.66M sold.

Based on aggregated 13F filings for Q4 2014.